ACST Stock – (NASDAQ: ACST) is providing an update on the usage
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or maybe the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually providing an update on the use of its “at-the market” equity providing plan.
As earlier disclosed, Acasti entered into an amended and restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and also H.C. Wainwright & Co., LLC (collectively, the “Agents”), to put into practice an “at-the market” equity offering program under which Acasti might issue and sell from time to time the common shares of its having an aggregate offering price of up to $75 million in the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as required pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January 27, 2021, Acasti issued an aggregate of 20,159,229 typical shares (the “ATM Shares”) with the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 million. The ATM Shares had been marketed at prevailing market prices averaging US$1.0747 per share. No securities had been offered throughout the facilities of the TSXV or perhaps, to the understanding of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate yucky proceeds raised was given to the Agents in connection with the services of theirs. As a result of the latest ATM sales, Acasti has a total of 200,119,659 typical shares issued and great as of March five, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and will supply the Company with additional flexibility in its ongoing review process to check out as well as evaluate strategic alternatives.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically focused on the research, commercialization and development of prescribed drugs using OM3 fatty acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have extensive clinical proof of efficacy and safety in lowering triglycerides in individuals with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being developed for patients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of that press release which aren’t statements of current or historical truth constitute “forward-looking information” within the meaning of Canadian securities laws and “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking claims include known and unknown risks, uncertainties, as well as other unknown components that can result in the actual outcomes of Acasti to be materially different from historical results and as a result of any future results expressed or even implied by such forward-looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, readers are actually urged to look at statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be forward-looking and uncertain. Readers are actually cautioned not to place undue reliance on these forward looking statements, which speak just as of the date of this particular press release. Forward-looking assertions in this press release include, but are not restricted to, statements or information about Acasti’s strategy, succeeding operations as well as the review of its of strategic alternatives.
The forward-looking claims contained in this press release are expressly qualified in their entirety by this cautionary declaration, the “Special Note Regarding Forward-Looking Statements” area contained in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10-Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at giving www.sedar.com as well as on the investor area of Acasti’s website at www.acastipharma.com. Many forward-looking claims in that press release are produced as of the date of this particular press release.
ACST Stock – Acasti doesn’t undertake to upgrade some such forward looking statements whether as a direct result of information that is new , future events or otherwise, except as needed by law. The forward-looking claims contained herein are also subject generally to risks and assumptions as well as uncertainties that are described from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, like Acasti’s latest annual report on Form 10 K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is giving an update on the usage